Kezar Life Sciences, Inc. (KZR) Accumulated Depreciation (2017 - 2024)

Kezar Life Sciences has reported Accumulated Depreciation for 8 years, with the latest figure at $6.2 million in Q3 2024.

• Quarterly Accumulated Depreciation rose 20.64% year-over-year to $6.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $6.2 million (up 20.64% YoY) and the FY2023 annual result came in at $5.4 million, up 17.77% from the prior year.
• Accumulated Depreciation climbed to $6.2 million in Q3 2024 per KZR's latest filing, from $5.9 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $6.2 million in Q3 2024 and troughed at $2.1 million in Q1 2020.
• A 5-year average of $4.1 million and a median of $4.1 million in 2022 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2020 and 2023: Accumulated Depreciation jumped 80.63% in 2020, then advanced 16.42% in 2023.
• Over 5 years, Accumulated Depreciation stood at $2.7 million in 2020, then soared by 33.19% to $3.7 million in 2021, then gained by 26.01% to $4.6 million in 2022, then rose by 17.77% to $5.4 million in 2023, then grew by 14.41% to $6.2 million in 2024.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $6.2 million, $5.9 million, and $5.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.